Applied Therapeutics, Inc.
APLT
$0.4601
-$0.0288-5.89%
| Weiss Ratings | APLT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | APLT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | APLT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.65 | |||
| Price History | APLT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -7.92% | |||
| 30-Day Total Return | -28.89% | |||
| 60-Day Total Return | -46.26% | |||
| 90-Day Total Return | -94.71% | |||
| Year to Date Total Return | -48.78% | |||
| 1-Year Total Return | -92.73% | |||
| 2-Year Total Return | -44.82% | |||
| 3-Year Total Return | -79.73% | |||
| 5-Year Total Return | -98.65% | |||
| 52-Week High % Change | -95.14% | |||
| 52-Week Low % Change | 19.22% | |||
| Price | APLT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $10.62 | |||
| 52-Week Low Price | $0.43 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Nov 11, 2024 | |||
| Valuation | APLT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 60.07M | |||
| Enterprise Value | -36.82M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.62 | |||
| Earnings Per Share Growth | 23.34% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -368.79 | |||
| Price/Book (Q) | 10.20 | |||
| Enterprise Value/Revenue (TTM) | 174.51 | |||
| Price | $0.46 | |||
| Enterprise Value/EBITDA (TTM) | 0.40 | |||
| Enterprise Value/EBIT | 0.40 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | APLT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 144.35M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | APLT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 212 220 9226 | |||
| Address | 545 Fifth Avenue New York, NY 10017 | |||
| Website | www.appliedtherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2016 | |||
| Profitability | APLT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 43,736.49% | |||
| Profit Margin | 88,772.51% | |||
| Management Effectiveness | APLT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -76.01% | |||
| Return on Equity | -- | |||
| Income Statement | APLT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -211.00K | |||
| Total Revenue (TTM) | -211.00K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | -91.17M | |||
| EBITDA (TTM) | -92.28M | |||
| EBIT (TTM) | -92.28M | |||
| Net Income (TTM) | -187.31M | |||
| Net Income Avl. to Common (TTM) | -187.31M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -61.89% | |||
| EPS Diluted (TTM) | -1.62 | |||
| EPS Diluted Growth (Q YOY) | -1.69% | |||
| Balance Sheet | APLT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 98.87M | |||
| Cash Per Share (Q) | $0.68 | |||
| Total Current Assets (Q) | 104.60M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 5.89M | |||
| Current Ratio (Q) | 1.057 | |||
| Book Value Per Share (Q) | $0.05 | |||
| Total Assets (Q) | 106.57M | |||
| Total Current Liabilities (Q) | 98.97M | |||
| Total Debt (Q) | 1.97M | |||
| Total Liabilities (Q) | 100.67M | |||
| Total Common Equity (Q) | 5.89M | |||
| Cash Flow | APLT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 0.00 | |||
| Cash from Financing (TTM) | 143.25M | |||
| Net Change in Cash (TTM) | 61.41M | |||
| Levered Free Cash Flow (TTM) | -3.58M | |||
| Cash from Operations (TTM) | -81.84M | |||
